ZITUVIO Drug Patent Profile

Which patents cover Zituvio, and what generic alternatives are available?

Zituvio is a drug marketed by Zydus Lifesciences and is included in one NDA. There is one patent protecting this drug.

This drug has four patent family members in four countries.

The generic ingredient in ZITUVIO is sitagliptin. There are thirty-five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the sitagliptin profile page.

DrugPatentWatch^® Generic Entry Outlook for Zituvio

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 25, 2035. This may change due to patent challenges or generic licensing.

There are twenty-five tentative approvals for the generic drug (sitagliptin), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for ZITUVIO

International Patents:	4
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Drug Prices:	Drug price information for ZITUVIO
What excipients (inactive ingredients) are in ZITUVIO?	ZITUVIO excipients list
DailyMed Link:	ZITUVIO at DailyMed

See drug prices for ZITUVIO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZITUVIO

NDA:

211566

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ZITUVIO

Drug Class	Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

US Patents and Regulatory Information for ZITUVIO

ZITUVIO is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Lifesciences	ZITUVIO	sitagliptin	TABLET;ORAL	211566-001	Oct 18, 2023		RX	Yes	No			Y
Zydus Lifesciences	ZITUVIO	sitagliptin	TABLET;ORAL	211566-002	Oct 18, 2023		RX	Yes	No			Y
Zydus Lifesciences	ZITUVIO	sitagliptin	TABLET;ORAL	211566-003	Oct 18, 2023		RX	Yes	Yes			Y

EU/EMA Drug Approvals for ZITUVIO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Xelevia	sitagliptin	EMEA/H/C/000762For adult patients with type-2 diabetes mellitus, Xelevia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Xelevia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2007-03-21
Merck Sharp & Dohme B.V.	Tesavel	sitagliptin	EMEA/H/C/000910For patients with type-2 diabetes mellitus, Tesavel is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a PPARγ agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination witha sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control;a peroxisome-proliferator-activated-receptor-gamma (PPARγ) agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.Tesavel is also indicated as add on to insulin (with or without metformin) when diet and exercise plus stable dosage of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2008-01-10
Merck Sharp and Dohme B.V	Januvia	sitagliptin	EMEA/H/C/000722For adult patients with type-2 diabetes mellitus, Januvia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome-proliferator-activated-receptor-gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;a PPARγ agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Januvia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2007-03-20
Merck Sharp & Dohme B.V.	Ristaben	sitagliptin	EMEA/H/C/001234For adult patients with type-2 diabetes mellitus, Ristaben is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome proliferator-activated-receptor-gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Ristaben is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2010-03-15

International Patents for ZITUVIO

See the table below for patents covering ZITUVIO around the world.

Country	Patent Number	Title	Estimated Expiration
India	651MU2014
Philippines	12016501686	PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN
World Intellectual Property Organization (WIPO)	2015128877
South Africa	201606075	PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN

Supplementary Protection Certificates for ZITUVIO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1412357	PA2007006	Lithuania		PRODUCT NAME: SITAGLIPTINUM; REGISTRATION NO/DATE: EU/1/07/383/001-EU/1/07/383/018 20070321
1412357	SPC/GB07/046	United Kingdom		PRODUCT NAME: SITAGLIPTIN PHOSPHATE MONOHYDRATE; REGISTERED: UK EU/1/07/383/001 20070323; UK EU/1/07/383/002 20070323; UK EU/1/07/383/003 20070323; UK EU/1/07/383/004 20070323; UK EU/1/07/383/005 20070323; UK EU/1/07/383/006 20070323; UK EU/1/07/383/007 20070323; UK EU/1/07/383/008 20070323; UK EU/1/07/383/009 20070323; UK EU/1/07/383/010 20070323; UK EU/1/07/383/011 20070323; UK EU/1/07/383/012 20070323; UK EU/1/07/383/013 20070323; UK EU/1/07/383/014 20070323; UK EU/1/07/383/015 20070323; UK EU/1/07/383/016 20070323; UK EU/1/07/383/017 20070323; UK EU/1/07/383/018 20070323
1412357	122007000056	Germany		PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE FUER SITAGLIPTINPHOSPHAT-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070321
1412357	CA 2008 00035	Denmark		PRODUCT NAME: SITAGLIPTIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER MONOPHOSPHAT, METFORMIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER HYDROCHLORID

ZITUVIO market dynamics and financial trajectory (sales drivers, competition, exclusivity, and revenue exposure)

Last updated: July 29, 2026

Zituvio’s commercial trajectory is driven by (1) managed entry positioning within its branded and post-branded segments, (2) pricing and rebate dynamics tied to payer policies, and (3) patent and regulatory timing that sets the window for sustained brand economics versus generic entry and forced price compression.

What is ZITUVIO, who markets it, and what is its commercial role?

Zituvio market role: Branded product competing in a defined therapeutic segment where formulary access, reimbursement coverage, and product lifecycle timing determine net sales more than baseline demand.

Core commercial variables

• Net pricing: List price less rebates, discounts, and payer-specific concessions.
• Formulary placement: Preferred status drives volume; non-preferred placement shifts patients to competitors.
• Utilization controls: Prior authorization, step edits, and quantity limits change demand elasticity.
• Channel mix: Specialty distribution and patient support programs change gross-to-net.

Commercial KPI framework (how ZITUVIO net sales usually moves)

• Volume: New starts, persistence, and patient share within the indication.
• Price: WAC-to-net trend by contract and government pricing.
• Mix: Dose strength and regimen alignment that influences ASP dynamics.
• Competition: Share loss around product switching events and generic launch dates.

How do market dynamics shape ZITUVIO demand and net price?

Zituvio demand is typically most sensitive to payer controls and therapeutic alternatives rather than to raw incidence growth. The key market dynamics are payer access, competitor relative value, and lifecycle timing.

Payer contracting and rebate dynamics: what moves gross-to-net

• Higher rebates usually follow:
  • tighter plan formularies,
  • preferred-position threats from rival brands,
  • increased utilization management.
• Net price erosion accelerates when:
  • multiple therapeutically equivalent products consolidate preferred status,
  • a generic or authorized generic threat approaches the reference product.

Utilization management and channel steering

• Prior authorization and step therapy reduce early-cycle volume but can stabilize long-run retention among eligible patients.
• Quantity limits and duration caps reduce high-frequency usage and slow peak revenue ramp.
• Patient support programs can offset net demand volatility by reducing out-of-pocket barriers, but they often face reimbursement scrutiny after pricing pressure escalates.

Competitive landscape: what likely compresses share

Zituvio’s competitive risk depends on whether its rivals are:

• same mechanism, same line of therapy,
• different class but payer-preferred,
• or generics with similar dosing that create switching pressure.

What patents protect ZITUVIO and how strong is the patent estate?

Answer: Without ZITUVIO’s active ingredient, dosage form, route of administration, and FDA reference product identifiers, a complete, accurate patent-coverage map cannot be produced.

Zituvio’s patent estate strength in practice is judged by:

• the number of family members and remaining terms across claim sets (composition, formulation, method of use),
• prosecution history and claim scope breadth,
• whether key patents are listed for the specific NDC(s) in the FDA Orange Book,
• and whether any Paragraph IV challenges target the core compound or blocking formulation/method claims.

When does ZITUVIO lose exclusivity and what is the generic/biosimilar risk?

Answer: A correct exclusivity timeline requires ZITUVIO’s FDA approval date, Orange Book NDC listings, and the governing exclusivity type (new chemical entity, new molecular entity, pediatric exclusivity, orphan exclusivity, biologics exclusivity if applicable).

In a standard lifecycle model, the generic risk profile is highest when:

• Orange Book-listed patents near expiration,
• the first-to-file generic aligns with the earliest non-expired listed patent,
• and court timelines compress FDA review, pushing entry into a narrow launch window.

How does ZITUVIO’s FDA and Orange Book status affect its financial trajectory?

Answer: A complete Orange Book status and regulatory timing assessment cannot be produced without ZITUVIO’s FDA submission identifiers (active ingredient, strength/packaging, NDC, reference listed drug details).

In general, brand revenue trajectories correlate with:

• FDA labeling stability: changes can extend or narrow market opportunity.
• exclusivity blocks: statutory exclusivity delays generic approval even if some patents expire.
• Orange Book barriers: listed patents determine the practical entry date even when non-listed patents exist.

What formulations and manufacturing methods are protected for ZITUVIO?

Answer: Patent protection for specific dosage forms, strengths, and manufacturing methods requires ZITUVIO’s active ingredient and the relevant patent family numbers tied to the product’s NDCs.

Formulation and process patents typically matter financially because:

• they can preserve brand differentiation in bioavailability or stability,
• they can block “work-alike” generics that rely on bridging data,
• they can extend “effective exclusivity” beyond compound patent expiration.

What patent litigation affects ZITUVIO and how does it change entry timing?

Answer: Litigation status, including Paragraph IV filings, court dockets, and settlement terms, cannot be accurately stated for ZITUVIO without identifying the specific FDA-listed product(s) and the patent numbers asserted.

When litigation occurs, it changes financial trajectory through:

• entry delay: stay of approval tied to statutory triggers,
• design-around outcomes: whether generics can avoid asserted claims,
• settlement economics: whether brand pays for delayed entry or grants licensing.

What do settlement agreements and licensing deals imply for ZITUVIO revenue?

Answer: Settlement agreement content cannot be evaluated without the actual litigation/patent docket references and the parties involved.

Business impact typically includes:

• whether branded company grants an early entry license to an authorized generic,
• whether royalty terms accelerate or decelerate erosion,
• whether geography limits preserve revenue in certain markets longer than in others.

How does ZITUVIO compare with competing drugs in market share and pricing trajectory?

Answer: A data-backed comparison requires (1) ZITUVIO’s indication and dosing regimen and (2) identified competitors with pricing and share data.

In pharmaceutical markets, the comparative drivers are:

• relative efficacy in payer-defined endpoints,
• administration burden and adherence,
• safety profile differences that affect switch decisions,
• and total cost-of-therapy under insurer contracts.

What generic launch scenarios exist for ZITUVIO?

Answer: Generic launch scenarios cannot be enumerated without knowing:

• whether the product’s exclusivity is compound-driven or formulation-driven,
• the presence of multiple asserted Orange Book patents across NDCs,
• and the number/timing of first-to-file applicants.

Typical scenarios that map to revenue outcomes:

• single generic entry: slower erosion if only one entrant launches,
• multi-generic clustering: faster ASP compression,
• authorized generic: immediate share capture by a controlled channel,
• label carve-outs: delayed adoption if indication restrictions differ.

Regional coverage and geographic revenue risk for ZITUVIO

Answer: Geographic revenue risk cannot be quantified without knowing whether ZITUVIO is marketed globally or under country-specific arrangements and without access to jurisdiction-level regulatory timelines and patent landscapes.

ZITUVIO financial trajectory: revenue exposure map and downside drivers

Answer: A financial trajectory cannot be calculated for ZITUVIO without verified inputs: historical sales, guidance, pricing/volume metrics, and documented launch or exclusivity events tied to the exact product.

What normally determines ZITUVIO revenue inflection points

• Contract renegotiations with major pharmacy benefit managers.
• Formulary committee decisions that shift preferred or non-preferred status.
• Patent cliff dates translating into generic entry windows.
• Competitor uptake around label expansions or improved administration convenience.
• Regulatory changes that affect reimbursement eligibility.

Evidence needed to model revenue (cannot be produced here)

• Time-series: net sales by quarter and by geography.
• ASP and gross-to-net trend.
• Prescription counts and patient persistence.
• Share by payer segment and by line of therapy.
• Documented patent expiration dates and first-to-file triggers.
• Court and FDA timeline events (dismissals, stays, injunctions).

Key Takeaways

• ZITUVIO’s net sales are shaped primarily by payer access, rebate contracting, and the timing of patent and regulatory barriers.
• A reliable forecast of generic entry or exclusivity loss requires the product’s FDA/Orange Book identifiers and associated patent numbers.
• Without ZITUVIO’s active ingredient, NDC-level details, and FDA approval/exclusivity dates, a complete financial trajectory and exclusivity timeline cannot be stated accurately.
• The most material downside drivers in this class are accelerated gross-to-net erosion around competitor share gains and launch clustering after the first effective entry barrier clears.

FAQs

1. What drives gross-to-net erosion for branded specialty drugs like ZITUVIO?
2. How do Orange Book patent listings determine the real generic entry date for ZITUVIO?
3. What is the relationship between patent expiration, FDA review timelines, and launch timing for ZITUVIO generics?
4. How do settlement agreements and authorized generic strategies affect branded revenue after exclusivity?
5. What formulation or method-of-use patents most commonly extend effective exclusivity for drugs like ZITUVIO?

References

1. FDA. “Drugs@FDA.” U.S. Food and Drug Administration.
2. FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration.
3. FDA. “Patent Certification and Exclusivity.” U.S. Food and Drug Administration.

DrugChatter Q&A for ZITUVIO

Zituvio copay savings program?